|
|
Volumn 2, Issue 3, 2005, Pages 115-
|
|
Cancer immunotherapy comes of age
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CANCER VACCINE;
INTERLEUKIN 2;
LYMPHOCYTE ANTIGEN;
MONOCLONAL ANTIBODY;
TUMOR ANTIGEN;
ADOPTIVE IMMUNOTHERAPY;
CANCER CELL;
CANCER CHEMOTHERAPY;
CANCER IMMUNIZATION;
CANCER IMMUNOTHERAPY;
CANCER RADIOTHERAPY;
CANCER REGRESSION;
CANCER SURGERY;
CELL TRANSFER;
DRUG APPROVAL;
DRUG FATALITY;
DRUG MECHANISM;
DRUG RESPONSE;
DRUG SAFETY;
EDITORIAL;
FOOD AND DRUG ADMINISTRATION;
GENE EXPRESSION;
HISTORY OF MEDICINE;
HUMAN;
IMMUNITY;
IMMUNOSTIMULATION;
KIDNEY CANCER;
LYMPHOCYTE;
MELANOMA;
PRIORITY JOURNAL;
TREATMENT OUTCOME;
CARCINOMA, RENAL CELL;
CLINICAL TRIALS;
HUMANS;
IMMUNOTHERAPY;
INTERLEUKIN-2;
KIDNEY NEOPLASMS;
MELANOMA;
NEOPLASMS;
SKIN NEOPLASMS;
|
|
EID: 20444436860
PISSN: 17434254
EISSN: None
Source Type: Journal
DOI: 10.1038/ncponc0101 Document Type: Editorial |
|
Times cited : (45)
|
|
References (0)
|